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Abstract: Uveal melanoma (UM) is the most common primary eye malignancy in adults and up to 50%
of patients subsequently develop systemic metastasis. Metastatic uveal melanoma (MUM) is highly
resistant to immunotherapy. One of the mechanisms for resistance would be the immune-suppressive
tumor microenvironment. Here, we have investigated the role of tryptophan 2,3-dioxygenase (TDO) in
UM. Both TDO and indoleamine 2,3-dioxygenase (IDO) catalyze tryptophan and produce kynurenine,
which could cause inhibition of T cell immune responses. We first studied the expression of TDO on
tumor tissue specimens obtained from UM hepatic metastasis. High expression of TDO protein was
confirmed in all hepatic metastasis. TDO was positive in both normal hepatocytes and the tumor cells
with relatively higher expression in tumor cells. On the other hand, IDO protein remained undetectable
in all of the MUM specimens. UM cell lines established from metastasis also expressed TDO protein and
increasing kynurenine levels were detected in the supernatant of MUM cell culture. In TCGA database,
higher TDO2 expression in primary UM significantly correlated to BAP1 mutation and monosomy 3.
These results indicate that TDO might be one of the key mechanisms for resistance to immunotherapy
in UM.
Keywords: uveal melanoma; metastatic uveal melanoma; liver metastatic; tryptophan 2,3-dioxygenase;
TDO; tryptophan; kynurenine; LCMS; tumor microenvironment; immunotherapy
1. Introduction
Uveal melanoma (UM) originates from melanocytes in the iris, ciliary body, and choroid.
The estimated incidence of UM is 5 per million in the United States [1], and between 2 to 8 cases
per million in Europe [2,3]. Up to 50% of patients develop metastatic disease, with the liver being
a predominant metastatic site in 70% to 90% of cases [4]. Despite advances in the treatment of primary
UM, treatment options for metastatic UM (MUM) remain limited [4,5].
UM displays chromosome aberrations and gene mutations that correlate strongly with clinical
outcomes. Loss of one copy of chromosome 3 (monosomy 3) and BAP1 mutation in primary UM is
associated with an increased risk of metastasis and a poor prognosis [6]. A previous study on TCGA
data found that the four subtypes of primary UM have distinct molecular signatures. Two subtypes
are associated with monosomy 3 (M3) and chromosome 8q gain with poor prognosis, and the other
Cancers 2020, 12, 405; doi:10.3390/cancers12020405 www.mdpi.com/journal/cancers
Cancers 2020, 12, 405 2 of 14
two are associated with disomy 3 (D3) and chromosome 6p gain with better prognosis [7]. Despite the
fundamental knowledge of the molecular phenotypes of UM, effective treatments for metastatic uveal
melanoma (MUM) have not been developed.
The recent development of immune checkpoint inhibitors (ICIs) revolutionized immunotherapy for
metastatic cutaneous melanoma (CM). Unfortunately, MUM is highly resistant to ICIs [8]. The reasons
underlying the poor responses to immunotherapy in MUM remain speculative. One of the mechanisms by
which tumors escape the immune system is through the upregulation and expression of immunosuppressive
molecules. Our laboratory investigated programmed death-1 (PD-1) and programmed death-ligand 1
(PD-L1) expression levels in MUM tissues and reported low expression of PD-L1 in hepatic metastasis from
UM, compared to metastasis from cutaneous melanoma [9]. PD-L1 can be expressed in metastatic UM cell
lines in response to interferon-gamma (IFN-γ) and this phenomenon indicates a lack of activated T cells in
MUM tumor microenvironment. Since tryptophan 2,3-dioxygenase (TDO) is predominantly expressed in
the liver, we speculated that TDO encoded by the TDO2 gene might play a role in T-cell non-inflamed
tumor microenvironment in the liver.
Under physiological conditions, the kynurenine (Kyn) pathway helps in carrying out metabolism
of tryptophan (Trp) to manage various essential metabolic pathways of the human body, including
NAD+ biosynthetic pathway and TCA cycle [10]. Further, Kyn pathway is now firmly established as
one of the key regulators of immunity [11,12]. Two enzymes, TDO and indoleamine 2,3-dioxygenase
(IDO), regulate the first and rate-limiting step of the Kyn pathway. IDO is expressed in many tumors
and induced by IFN-γ to contribute to tumoral resistance to immune rejection [13]. In contrast, the liver
constitutively expresses TDO and is one of the major organs for TDO-mediated metabolism of Trp to
Kyn. Moreover, TDO has a higher capacity for Trp than IDO in the human liver [10]. In terms of the
role of TDO in cancer, TDO is strongly expressed in various cancers including glioma and TDO-derived
Kyn promoted glioma cell survival and migration thorough the aryl hydrocarbon receptor (AHR)
activation in an autocrine/paracrine fashion [14–16].
Trp is an essential amino acid and is required for T cell and NK cell functions, whereas the
metabolically-generated Kyn suppresses the proliferation of T cells and NK cells and makes them
sensitive to apoptosis stimuli [12,15,17]. The catabolites of Trp in tumor microenvironment is responsible
for immune response suppression and consequently prevents tumor cells from immunological
rejection [18].
Hence, in the present work, we investigated the expression of TDO2 mRNA and TDO protein in
hepatic metastasis tissue specimens, as well as cell lines collected from stage IV UM patients. Using
liquid chromatography high resolution mass spectrometry (LC-HRMS), we aimed to confirm that TDO
in MUM cells is functional and increases Kyn levels in culture media. We also investigated TDO2
mRNA expression in the TCGA database of primary UM and correlated it with a prognostic outcome.
Our data suggest that TDO expressed by UM cells might be one of the key mechanisms for resistance
to immunotherapy in UM.
2. Results
2.1. The Detection of (TDO) Protein by IHC in MUM Tissue Sections
We first investigated whether TDO protein is detectable in MUM tissues. Immunohistochemical
(IHC) staining of TDO protein in 16 archived hepatic metastasis samples from stage IV UM patients
show presence of TDO protein in all specimens (Figure 1A,D and Figure S1). The expression of TDO
is detected in both melanoma and noncancerous areas of liver tissue in all patients (Figure 1 and
Figure S1). The specificity of TDO antibody was confirmed by blocking peptides. In contrast, IDO
is found to be negative in all MUM tissue sections (0/14) (Figure 1C,F and Figure S1). Interestingly,
the intensity of TDO staining tended to be higher in metastatic melanoma cells themselves (Figure 1B,E
and Figure S1), compared to that of surrounding normal hepatocytes (Figure 1 and Figure S1). The data
obtained from IHC staining of MUM tissues indicate a special role of TDO in MUM.
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Figure 1. Immunohistochemical (IHC) staining of liver metastasis specimens. Liver metastasis 
specimens were stained for TDO, HMB45, and IDO. Positive cells show a distinct red stain. IHC 
staining of two representative sets of archived liver metastasis specimens were shown. (A,D) TDO 
staining: For negative control, TDO antibody was blocked with specific blocking peptide (a,d). 
Magnification: ×100 (left panels); ×200 (right panels) Scale bar = 100 μm. (B,E) HMB45 staining: 
Melanoma metastasis is positive (right bottom) and surrounding liver tissue is negative (right top). 
Isotype-matched IgG was used as negative control (b,e). Magnification: ×100 (left panels); ×200 (right 
panels) Scale bar = 100 μm (C,F) IDO staining: IDO is negative for both metastatic melanoma and 
surrounding liver tissue (top). Isotype-matched IgG is used as negative control (c,f). Magnification: 
×100. Scale bar = 100 μm. 
2.2. RNA with in Situ Hybridizations in the MUM Tissue Sections 
To further confirm the specificity of anti-TDO antibody, detection of TDO2 mRNA was carried 
out with the RNAscope method in the hepatic metastasis tissue sections. We used an in-situ 
hybridization assay to detect TDO2 mRNA within intact cells. As shown in Figure 2, melanoma cells 
and surrounding liver tissue show positive TDO2 mRNA expression (Figure 2a–c,f–h). Staining of 
TDO2 mRNA is much stronger in MUM cells (Figure 2c,h) compared to the surrounding liver tissues 
(Figure 2b,g). TDO protein is also positive in the area where TDO2 mRNA expression is positive 
(Figure 2d,i). The tissues were also stained with HMB45 to confirm melanoma cells (Figure 2e,j). 
These data confirm that TDO is dominantly expressed in MUM cells in the liver. In addition to the 
physiological presence of TDO in hepatocytes, enriched expression of TDO was confirmed in uveal 
melanoma cells. 
Figure 1. Immunohistochemical (IHC) staining of liver metastasis specimens. Liver metastasis specimens
were stained for TDO, HMB45, and IDO. Positive cells show a distinct red stain. IHC staining of two
representative sets of archived liver metastasis specimens were shown. (A,D) TDO staining: For negative
control, TDO antibody was blocked with specific blocking peptide (a,d). Magnification: ×100 (left panels);
×200 (right panels) Scale bar = 100 µm. (B,E) HMB45 staining: Melanoma metastasis is positive (right
bottom) and surrounding liver tissue is negative (right top). Isotype-matched IgG was used as negative
control (b,e). Magnification: ×100 (left panels); ×200 (right panels) Scale bar = 100 µm (C,F) IDO staining:
IDO is negative for both metastatic melanoma and surrounding liver tissue (top). Isotype-matched IgG is
used as negative control (c,f). Magnification: ×100. Scale bar = 100 µm.
2.2. RNA with in Situ Hybridizations in the MUM Tissue Sections
To further confirm the specificity of anti-TDO antibody, detection of TDO2 mRNA was carried out
with the RNAscope method in the hepatic metastasis tissue sections. We used an in-situ hybridization
assay to detect TDO2 mRNA within intact cells. As shown in Figure 2, melanoma cells and surrounding
liver tissue show positive TDO2 mRNA expression (Figure 2a–c,f–h). Staining of TDO2 mRNA is much
stronger in MUM cells (Figure 2c,h) compared to the surrounding liver tissues (Figure 2b,g). TDO
protein is also positive in the area where TDO2 mRNA expression is positive (Figure 2d,i). The tissues
were also stained with HMB45 to confirm melanoma cells (Figure 2e,j). These data confirm that TDO is
dominantly expressed in MUM cells in the liver. In addition to the physiological presence of TDO in
hepatocytes, enriched expression of TDO was confirmed in uveal melanoma cells.
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stain. Metastatic uveal melanoma cells show stronger and distinct staining (c,h) compared to the 
surrounding liver (b,g). Staining with unrelated control probe is shown as negative control in the 
mid-left inserts. TDO protein staining (d,i): Areas positive for in situ staining of TDO2 RNA are also 
strongly positive for TDO protein. Staining with isotype-matched control antibody is shown in the 
mid-left inserts. HMB45 staining (e,j): The areas strongly positive for TDO2 RNA (c,h) and TDO 
protein are also positive for HMB45. Neighboring liver tissue with much weaker staining for TDO2 
RNA (b,g) and TDO protein is negative for HMB45. Staining with isotype-matched control antibody 
is shown in the mid-left inserts. Magnification: ×100 (a,d,e,f,i,j) Scale bar = 100 μm; ×400 (b,c,g,h) Scale 
bar = 20 μm. 
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MUM cell lines are positive for TDO2 mRNA. In contrast, two out of four cell lines are IDO1 mRNA 
clearly positive. The expression of TDO protein in MUM cell lines is also confirmed using Western 
blotting (Figures 3B and S2). However, IDO protein expression is found to be negative in all 
metastatic UM cell lines. Once melanoma cells were stimulated with IFN-γ for 48 h, IDO protein 
became detectable (Figures 3B and S2). The result indicates that TDO protein is constitutively 
expressed in the MUM cells, whereas MUM cells express IDO protein only when they encounter IFN-
γ. 
 
Figure 3. Expressions of TDO and IDO in MUM cell lines. (A) IDO1 and TDO2 mRNA expressions 
were evaluated by RT-PCR. GAPDH was used as a loading control. (B) TDO and IDO protein 
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Figure 2. Localization of TDO2 RNA and T i in hepatic metastasis specimens (Case 15 and
16). In situ hybridization of TDO2 RNA (a–c,f–h): Positive cells with TDO2 RNA sho a distinct
red stain. Metastatic uveal melanoma cells show stronger and distinct staining (c,h) compared to the
surrounding liver (b,g). Staining with unrelated control probe is shown as negative control in the
mid-left inserts. TDO protein staining (d,i): Areas positive for in situ staining of TDO2 RNA are also
strongly positive for TDO protein. Staining with isotype-matched control antibody is shown in the
mid-left inserts. HMB45 staining (e,j): The areas strongly positive for TDO2 RNA (c,h) and TDO
protein are also positive for HMB45. Neighboring liver tissue with much weaker staining for TDO2
RNA (b,g) and TDO protein is negative for HMB45. Staining with isotype-matched control antibody is
shown in the mid-left inserts. Magnification: ×100 (a,d,e,f,i,j) Scale bar = 100 µm; ×400 (b,c,g,h) Scale
bar = 20 µm.
2.3. The Expression of TDO and IDO in MUM Cell Lines
To test the enzymatic functions of TDO in MUM cells, the presence of TDO2 mRNA and TDO
protein were first investigated in established MUM cell lines. As showed in Figure 3A, all tested
MUM cell lines are positive for TDO2 mRNA. In contrast, two out of four cell lines are IDO1 mRNA
clearly positive. The expression of TDO protein in MUM cell lines is also confirmed using Western
blotting (Figure 3B and Figure S2). However, IDO protein expression is found to be negative in all
metastatic UM cell lines. Once melanoma cells were stimulated with IFN-γ for 48 h, IDO protein
became detectable (Figure 3B and Figure S2). The result indicates that TDO protein is constitutively
expressed in the MUM cells, wher as MUM ll express IDO protein only when they encounter IFN-γ.
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Figure 3. Expressions of TDO and IDO in MUM cell lines. (A) IDO1 and TDO2 mRNA expressions were
evaluated by RT-PCR. GAPDH was used as a loading control. (B) TDO and IDO protein expression in
MUM cell lines. β–actin was used as a loading control.
2.4. Expressions of TDO2 and IDO1 in Response to TNF-α and IFN-γ
It has been reported that various molecules are upregulated in tumor microenvironment in
response to immunological attack against cancer cells. Especially, Th1 type cytokines, such as IFN-γ
and TNF-α, are known to trigger upregulation of counter-attack molecules, including IDO and PD-L1.
We tested the effect of inflammatory cytokines commonly found in tumor microenvironment including
IL-1β, IL-6, IL-10, TNF-α, and IFN-γ on TDO2 expression on MUM cells. As shown in Figure 4A,
TNF-α at a dose of 1 to 10 ng/mL increases the expression of TDO2 mRNA substantially in UM004
cell line, while TNF-α had little effect on the expression of IDO. IL-1β, IL-6, and IL-10 did not induce
the expression of either TDO or IDO. When we examined the other three MUM cell lines, we found
an increase in the TDO2 mRNA by 2–8 folds (compared to untreated MUM cell lines) at the dose of
10 ng/mL of TNF-α. Moreover, IFN-γ stimulates expression of IDO1 but does not induce TDO2 mRNA
in MUM cells (Figure 4B). These data indicate that TNF-α, not IFN-γ, might stimulate upregulation of
TDO2 mRNA by MUM cells in a tumor microenvironment.
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2.5. Measurement of Kynurenine (Kyn) Metabolite Produced by MUM Cell Line
We further investigated whether TDO in MUM cells is functional. This is confirmed by measuring
Kyn concentration in the culture supernatant from the UM004 cells. Since TNF-α upregulated TDO2
RNA expression, we investigated production of Kyn by MUM cells in response to TNF-α. In contrast,
IFN-γ did not change the TDO2 RNA expression level; therefore, the influence of IFN-γ on Kyn
production was not tested in this assay. Kyn levels in the supernatant from UM004 cells are significantly
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increased after 24 h culture (Figure 5). In addition, the addition of TNF-α further increases Kyn levels
in the culture supernatant of UM004 cells (Figure 5), which is consistent with the upregulation of TDO2
expression by TNF-α (Figure 4A).
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2.6. The Role of TDO2 RNA Expression in Primary Uveal Melanoma
TDO2 is located at 4q32.1 and ubiquitously expressed throughout all 33 cancer types included
within the TCGA cohort (Figure 6A). While TDO2 RNA shows a range of expression profiles across the
cancers, the UM cohort consisting of 80 primary UM displays the lowest median expression. We then
analyzed the survival comparing the subjects with TDO2 RNA expression vs. those without TDO2
RNA expression. The expression of TDO2 RNA has no association with survival (p = 0.77) in this
comparison. Within the UM dataset itself, less than 50% of primary uveal melanomas (34/80) have
a detectable expression of TDO2 RNA (Figure 6B). While expression of TDO2 RNA is generally low
in primary UM, we further examined if the expression is correlated to clinical or genomic attributes
(Table S1). For 34 primary UM patients with positive TDO2 RNA expression, we stratified them
based upon clinical or molecular attributes and determined if these correlated to the TDO2 RNA
expression. We found that patients with BAP1 mutations have increased expression of TDO2 (p = 0.007)
compared to BAP1 wild-type. Similarly, patients with monosomy 3 (M3) primary uveal melanoma
have increased TDO2 RNA expression (p = 0.001). We then stratified the expression of TDO2 RNA
into four distinct cluster groups according to chromosomes 3, 6, and 8 copy-number aberrations [7].
Data were assessed to Cluster 1: Disomy 3 (D3) with enriched chromosome 6p; Cluster 2: D3 with
chromosome 6p gain with partial chromosome 8q gain; Cluster 3: M3 with chromosome 8q gain; and
Cluster 4: M3 with increased copy numbers of chromosome 8q gain. TDO2 RNA expression is higher
in Cluster 4 which has been associated with UM metastasis and poor prognosis in TCGA database
(Figure 6C).
Interestingly, when we focused on only patients whose tumor expresses TDO2 (n= 34), the survival
of patients with high TDO2 RNA expression (those above the median) showed shorter survival
compared to patients with low TDO2 RNA expression (those below the median) (p = 0.007) (Figure 7).
Taken together, these data suggest that in primary UM, TDO2 RNA expression is generally
low (compared to other cancers), but the increased TDO2 RNA expression is associated with the
poor prognosis markers, BAP1 mutations, and M3. More importantly, the degree of expression in
TDO2-positive primary UM correlated to the survival of patients.
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Figure 6. TDO2 expression in primary uveal melanoma. (A) Identification of TDO2 RNA expression
across other cancer types in the TCGA database. The first box shows UM data. The y-axis is a type of
cancer (Abbreviation in Table S2). The x-axis is a log2 FPKM values. (B) 34 primary uveal melanoma
tissue samples with positive TDO2 RNA. The x-axis shows individual IDs from TGCA data. The y-axis
is a log2 FPKM values. (C) TDO2 mRNA expression, grouped by somatic copy number alterations
(SCNAs) clusters. Dots show all data values. The y-axis is a log2 FPKM values for TDO2 RNA. Box plots
show median values, and the 25th to 75th percentile range in the data, i.e., the interquartile range (IQR).
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3. Discussion
Despite successful treatment with immune checkpoint inhibitors (ICIs) in metastatic cutaneous
melanoma [19], the efficacy of these medications is limited in MUM [20]. Previously reported clinical
trials with more than 30 MUM patients showed the response rates of anti-CTLA-4 antibody (ipilimumab)
and anti-PD-1 antibodies (nivolumab and pembrolizumab) to be 0–7.7% and 3.6–5.8%, respectively [21].
A variety of mechanisms may account for such resistance to ICIs, including low tumor mutational
burden and low tumor neoantigen expression [22]. Another unique characteristic of UM is that the
majority of metastases first develop in the liver. The liver is highly specialized in the development
of immune tolerance to food-derived antigens and provides MUM cells with a niche for survival by
decreasing immunological attacks by the host immune system.
It has been reported that tumor-infiltrating T cells obtained from MUM were difficult to expand
ex vivo. PD-L1 is not expressed in the liver metastasis from UM. The lack of PD-L1 expression
in tumor tissues and low expansion of CD8 T cells suggest that the liver is a challenging immune
microenvironment for tumor-specific T cells [23]. We hypothesized that one of the mechanisms
that contribute to deficient T cell immune responses in the liver metastasis is TDO-mediated Trp
catabolism, since the liver is rich in TDO. Conversion of Trp into Kyn (in presence of TDO) causes Trp
starvation in the microenvironment which suppresses immune cell functions [24]. Apart from having
immune suppression induced by Trp catabolism, Kyn binds to the aryl hydrocarbon receptor (AHR),
a cytoplasmic transcription factor. TDO-derived Kyn suppresses antitumor immune responses and
promotes tumor-cell survival and motility through the AHR in an autocrine/paracrine fashion [14]. Kyn
induces formation of regulatory T cells (T regs) and the administration of a TDO inhibitor improves
the function of dendritic cells (DCs) and decreases lung cancer metastasis in mice [14].
Much to our surprise, we confirmed that not only hepatocytes, but also MUM cells themselves,
express TDO. We demonstrated the expression of TDO2 mRNA and TDO protein in tumor tissue
specimens from MUM patients as well as MUM cell lines. This is the first demonstration of TDO2
mRNA as well as functional TDO protein in MUM tumors. Universal and constitutive expression of
TDO in MUM cells suggest an important role of TDO in the survival and progression of MUM cells.
Although the MUM cell line was able to express IDO in the presence of IFN-γ, IDO was shown to
be negative in archived hepatic metastasis samples from stage IV UM patients. This indicates the
important role of TDO in MUM in the liver to suppress immunological activities and potentially
promote the progression of the disease.
It is interesting that there is no survival difference in primary UM patients with and without TDO2
RNA expression in TCGA data. On the other hand, a clear survival difference is indicated between
patients with TDO2 high and TDO2 low primary UM. It could be speculated that TDO does not have
any meaningful role in tumors that do not express TDO. There are many different immune suppressive
mechanisms in cancer cells and a different immuno-modulatory mechanism would exist in primary
UM without TDO expression. On the other hand, in UM with expression of TDO2, the degree of TDO2
mRNA expression would influence the outcome of patients. It would also be possible that primary UM
without TDO2 expression starts expressing TDO in response to a factor in the tumor microenvironment.
We identified that one of such factors could be TNF-α. This might be supported by the fact that TDO2
RNA is dominantly expressed in Cluster 4 primary UM, in which significant infiltration of immune
cells are present. This possibility is further supported by our findings that all metastatic specimens
that we tested were positive for TDO protein and TDO2 mRNA. TDO expression in normal liver tissue
would provide additional protection to MUM cells from an immune attack by the host immune system.
The biological and clinical correlation with TDO has been tested in triple negative breast cancer
(TNBC). Co-culturing of CD8+ T cells with conditioned media from TDO-positive TNBC cells decreased
IFN-γ level and increased apoptosis of CD8+ T cells [25]. Higher expression of TDO in TNBC correlated
with poor overall survival (OS) [16]. Publicly available data confirmed that higher expression of TDO2
RNA in breast cancers correlated with worse OS and decreased distant metastasis-free survival, which
is inconsistent with our data on primary uveal melanoma with TDO2 RNA expression. However,
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there was no difference in OS and metastasis-free survival between these groups with IDO1 RNA
expression [25].
The expression of TDO2 RNA from the TCGA database also shows a correlation between TDO2
mRNA expression and poor prognostic markers (BAP1 mutation and Monosomy 3 (M3)) in UM. It is
also of note that M3 primary UM is associated with the presence of an inflammatory infiltrate and
expression of IDO, CTLA4, and PD-L1 [7,26]. To date, the regulation of TDO2 (in comparison to IDO)
expression has been poorly understood. Triple-negative breast cancer (TNBC) induced TDO2 mRNA
in co-culture with TNF-α and IL-1β This increase is through NF-κβ activation [16]. Our data support
this possibility and showed that when TNF-α, activator for NF-κβ, was added to the MUM cell culture,
it further increased TDO2 mRNA in MUM cells. At this moment, we are not sure whether expression
of TDO2 RNA in high risk primary UM is related to molecular or genetic alternation in UM cells or in
response to an inflammatory tumor microenvironment, as seen in Cluster 4 UM. Further investigation
is needed to answer this important question.
It is of note that the expression of IDO was associated with a poor prognosis in various malignancies.
Therefore, the efficacy of the IDO inhibitor in combination with various drugs was investigated in
ECHO301-310 trials. Unfortunately, the results of phase III trial (ECHO301) in melanoma indicated
that IDO-inhibitor treatment, in combination with anti-PD-1 antibody, showed no improvement
in progression-free survival compared to the anti-PD-1 antibody alone [27]. These results raise
fundamental questions about the benefit of IDO inhibitors in cancer treatment. One of the reasons for
trial failure could be explained by the fact that the tested IDO inhibitor does not cross-inhibit TDO.
Endogenous expression of TDO in various cancers and in the liver may inhibit T cell activities in the
tumor microenvironment and counteract the pharmacological effects of IDO specific inhibitors. In this
regard, dual inhibitors of IDO and TDO might need to be tested in future clinical trials.
Despite potential benefits from TDO inhibitor, a large-scale clinical study has not been done,
mainly due to toxicity concern. In a normal physiological condition, TDO is mainly expressed in the
liver, which is very important for controlling excess Trp levels [28]. Since TDO performs important
physiological functions, inhibiting TDO may have serious side effects. In this regard, inhibition of
TDO for 3 months did not show a difference in the level of hepatic toxicity between untreated and
treated mice [18]. Transgenic mice that did not express TDO did not exhibit any negative biological
activities [29]. In addition to safety concerns, we speculate that dual inhibitors for TDO and IDO need
to be considered due to compensatory roles of these enzymes. It is possible that tumor cells start
upregulating IDO after TDO inhibitor treatment as a compensatory mechanism of Trp-Kyn pathway or
in response to IFN-γ production by activated tumor-infiltrating T cells after blocking TDO.
Taken together, TDO2 expression in UM indicates poor prognosis, which is consistent with the
results of other types of cancers [15]. The presence of TDO2 RNA and TDO protein in all tested MUM
tissues indicate that TDO could be associated with the development and growth of metastasis in UM.
Furthermore, the development of metastasis in the liver might have an additional advantage, since the
liver is the major physiological source of TDO. TDO might support cancer metastasis and progression
of disease by affecting anti-cancer immunity or by promoting growth via AHR activation. TDO/IDO
inhibitor should have a potential role in improving the efficacy of immunotherapy against MUM and
could possibly prolong the survival of MUM patients.
4. Materials and Methods
4.1. Tissue Specimens
Formalin-fixed paraffin-embedded sections were collected from 16 stage IV UM patients. This study
was reviewed and approved by the institutional review board at Thomas Jefferson University (IRB
#02.9014R and #11E.548).
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4.2. Cell Lines and Cell Culture Studies
MUM cell lines (UM001, UM002B, UM004, and UMp005) were established from MUM tissue
specimens obtained from UM patients and characterized in our laboratory. Characteristics of these
cell lines were previously reported [30,31]. UMp005 was newly established from a PDX mouse model
and it was confirmed to have BAP1 mutation at c.828dupT and GNA11 Q209L mutation by Sanger
sequencing (Figure S3A). UMp005 cells expressed human melanoma markers, including HMB45 and
human high molecular weight-melanoma-associated antigen (HMW-MAA) detected by flow cytometry
(Figure S3B). All cell lines were authenticated by short tandem repeat (STR) (ATCC, Manassas, VA,
USA). UM001 cells were cultured in RPMI1640 supplemented with 10% fetal bovine serum (FBS), 4 mM
L-glutamine, 1% nonessential amino acids, 100 IU penicillin, and 100 µg/mL streptomycin. UM002B
and UMp005 cells were cultured with EMEM supplemented with 15% FBS, 100 IU penicillin, and
100 µg/mL streptomycin. UM004 cells were cultured with EMEM supplemented with 10% FBS, 100 IU
penicillin, and 100 µg/mL streptomycin. They were confirmed mycoplasma negative determined by
MycoProbe® (R&D systems, Minneapolis, MN, USA).
4.3. Data Collection from Publicly-Available Datasets
TCGA database contains DNA and RNA-sequence expression data for over 10,000 patients
representing 33 distinct cancer types [26,32]. Included in our analyses were 80 primary UM samples.
Normalized gene expression data files were downloaded from the genomic data commons (GDC)
data portal for 10,258 samples across the 33 cancers. The normalized RNA-sequence as fragments per
kilobase of transcript per million mapped reads (FPKM) were used. In addition to these data, clinical
information on these 80 UM patients was also retrieved from GDC. This data included all relevant
pathological and clinical information and overall prognostic outcomes. Finally, mutation information
for the commonly-mutated UM genes (BAP1, GNAQ, GNA11, EIFA1X, and SF3B1) was retrieved.
As TDO2 mRNA expression may correlate with somatic copy number alterations (SCNAs) clusters [7],
the difference of TDO2 expression among SCNAs clusters was compared. To determine an association
between TDO2 expression and BAP1 mutations, we first stratified patients as being BAP1 wild-type
versus having a BAP1 alteration. The remaining parameters were stratified based upon being below
or above the mean value of the gene. In this manner, the samples were split into two groups and
expression of their TDO2 computed in each group. From these two groups, a two-tailed t-test was
performed on the normalized TDO2 expression values. Kaplan-Meier analyses were performed to
determine OS associations. A log-rank test was used to compute the significance of survival difference.
4.4. Immunohistochemistry (IHC)
Formalin-fixed paraffin-embedded (FFPE) tissue sections (4–5 micrometer) were deparaffinized in
a series of xylenes and a series of graded ethanol. Antigen retrieval was performed by a heat-mediated
method in 10 mM sodium citrate buffer at pH 6.0 for TDO-targeted antigen, in 10 mM citric acid buffer
at pH 6.0 for IDO, and in Tris-EDTA buffer at pH 9.0 for HMB45 in a steamer for 20 min. Slides were
washed in tris-buffered saline with 0.025% tween 20. Tissue sections were blocked for endogenous
peroxidase and alkaline phosphatase by Bioxall (Vector Laboratories, Burlingame, CA, USA) followed
by 10% normal horse serum prior to primary antibody incubation for 2 h. Tissue sections were
incubated with anti-human TDO (#LS-B5791; dilution 1:200, LifeSpan BioSciences, Seattle, WA, USA),
IDO (#D5J4ETM; dilution 1:400, Cell Signaling), HMB45 (#M0634; dilution 1:100), or isotype control
(both from Aligent, Santa Clara, CA, USA) antibodies overnight at 4 ◦C. To check the non-specific
binding of anti-TDO antibody, an anti-TDO antibody was first incubated with blocking peptides
(LifeSpan BioSciences) that interfere with the binding of the anti-TDO antibody to TDO at the final
concentration of 1 µg/mL for 30 min at room temperature. The tissue sections were then incubated
with peptide-blocked TDO antibody overnight at 4 ◦C. The primary antibody was washed out and
the tissue sections were incubated with ImmPRESS UNIVERSAL reagent (Vector Laboratories) for
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30 min, followed by washing with 0.1% tween 20 in tris-buffered saline. The color was developed by
ImmPACT VECTOR RED AP (Vector Laboratories). Slides were counterstained with hematoxylin
(Vector Laboratories). The intensity of TDO staining of hepatic metastasis was captured using NikonTM
Eclipse 50i microscope with NIS-Elements D3.1 software (Nikon, Melville, NY, USA).
4.5. RNAscope® Assay
Tissue sections were also evaluated by TDO2 RNA in situ hybridization with a commercially
available kit (Advanced Cell Diagnostics, Inc., Newark, CA, USA) according to the manufacturer’s
instructions. Sample quality was validated using probes representing positive (PPIB) and negative
(DapB) controls. Briefly, FFPE tissue blocks were sectioned at 5 µm onto Frost Plus slides. Slides were
baked for 1 h at 60 ◦C prior to use. After deparaffinization and dehydration, the tissues were air-dried
and treated with peroxidase blocker before boiling for target retrieval in a pretreatment solution for
15 min. Protease was then applied for 30 min at 40 ◦C. The target probe (TDO2 mRNA) and control
probes were hybridized for 2 h at 40 ◦C, followed by a series of signal amplification and washing steps.
Hybridization signals were detected by chromogenic reactions using a red chromogen. Specific RNA
staining was identified as red punctate dots. Following the RNAscope staining procedures, samples
were counterstained for 2 min with Hematoxylin. Images were captured with a NikonTM Eclipse 50i
microscope with NIS-Elements D3.1 software.
4.6. RT-PCR
RNA from the UM cell lines was isolated according to the manufacturer protocol (Qiagen,
Valencia, CA, USA). Isolated RNA (2.5 µg) was used for the synthesis of complementary DNA using
the Superscript III First-Strand Synthesis System for RT-PCR and Oligo (dT)20 primer according to
the manufacturer’s protocol (Invitrogen, Carlsbad, CA, USA). Fragments of cDNA were amplified
using Platinum Taq DNA Polymerase (Invitrogen). The primers used for TDO2 and IDO1 detection
were shown in Table S3. For TDO2 RNA detection, we used the following conditions: 5 min at 94 ◦C,
31 cycles (94 ◦C for 1 min, 56 ◦C for 1 min, and 72 ◦C for 1 min), and 10 min at 72 ◦C amplified to a 601
bp fragment. The IDO1 primers were run in the following conditions: 5 min at 94 ◦C, 31 cycles (94 ◦C
for 1 min, 61 ◦C for 1 min, and 72 ◦C for 2 min), and 10 min at 72 ◦C amplified to a 1278 bp fragment.
The GAPDH primers (Table S3) were amplified to a 452 bp fragment in the following conditions: 5 min
at 94 ◦C, 30 cycles (94 ◦C for 30 s, 62 ◦C for 30 s, and 72 ◦C for 1 min), and 10 min at 72 ◦C. Then
each reaction mixture and ladder marker were loaded on a 1.7% agarose gel and analyzed with gel
electrophoresis. RT-PCR products were visualized using GelRed Nucleic Acid Stai RGB-4103 (Phenix,
Candler, NC, USA) under ultraviolet light.
4.7. Quantitative PCR
UM cells were seeded at the concentration of 3 × 106 in 100-mm plate and various concentrations
of recombinant human (rh) TNF-α, rhIL-6, rhIL-1β, and rhIFN-γ (PeproTech, Inc, Rocky Hill, NJ, USA)
or no cytokine was added and incubated for 24 h. Total RNA was collected and complementary DNA
was synthesized using SuperScript VIVO (Invitrogen). To determine gene expression level of TDO2 or
IDO1, quantitative PCR was performed using PowerUp SYBR Green Master Mix (Applied Biosystems,
Foster City, CA, USA), and data analysis was performed using Quant Studio 12K Flex Real-Time PCR
instrument (Applied Biosystems). The TDO2 expression was normalized to RNA loading for each
sample using GAPDH mRNA as an internal standard. All experiments were performed in triplicate.
All PCR conditions were determined by a melting curve analysis.
4.8. Western Blotting
Cultured UM cell lines were homogenized in a lysis buffer (Thermo Scientific, Waltham, MA, USA)
with a protease inhibitor cocktail. After centrifugation at 12,000 rpm for 15 min at 4 ◦C, supernatants
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were collected. Total protein was quantified using the Bradford protein assay (Bio-Rad, Hercules, CA,
USA). Protein (20 µg) was separated by a 4–20% SDS-PAGE (Invitrogen) and transferred to PVDF
membrane. Membranes were blocked with a blocking buffer (Invitrogen) at room temperature for 1 hr.
The membrane was incubated with primary antibodies at 4 ◦C overnight: mouse anti-human TDO
antibody purchased from Abnova (#H00006999-B01P; dilution 1:500, San Jose, CA, USA), anti-human
IDO antibody (#D5J4ETM; dilution 1:1000) and anti-human β-actin antibody (#D6A8; dilution 1:10,000)
purchased from Cell Signaling Technology (Beverly, MA, USA). The membranes were further incubated
with secondary antibody, a horseradish peroxidase-conjugated anti-mouse IgG antibody for TDO,
or anti-rabbit antibody for IDO and β-actin (both from Cell Signaling) for 1 h at room temperature.
Signal was developed using the Westfemto substrate (Thermo Scientific), and image was scanned with
C-DiGit blot scanner (LI-CDR, Lincoln, NE, USA).
4.9. Detection of Kynurenine (Kyn) Levels in Culture Supernatants
UM004 cells were seeded at 2.5 × 105 cells per well with 500 µL culture medium without FBS in
a 48-well plate. The culture medium was harvested after 24 h incubation, centrifuged, and frozen
until further analysis. Original culture medium and standards with known concentration of Kyn were
used for standardization of assay. Kyn reference standards were obtained from Sigma-Aldrich Corp
(St. Louis, MO, USA). HPLC-MS-grade acetonitrile (ACN), HPLC-MS grade water (with and without
0.1% formic acid (FA)), and FA were purchased from Fisher Scientific (Fair Lawn, NJ, USA).
Reverse-phase, isocratic elution chromatography was performed using HPLC-MS (Thermo Fisher,
Waltham, MA, USA), for detection and quantitation of Kyn. The mass spectrometer was calibrated in
positive ion mode with a mass error of 0.2 to 0.3 parts per million (ppm). The scanning mass range
was set as 190 to 211 m/z. This mass spectrometer method was used for the detection of Kyn eluted
from Dionex Ultimate 3000 HPLC system. Separation of Kyn was carried out on C18 reverse phase
(3.5 µm particle size, 4.6 × 75 mm) XBridge column by Waters (Milford, MA, USA). Standards and
samples were eluted using 20% ACN with 0.1% FA in distilled water. The injection volume was set
to 2 µL with a solvent flow rate of 0.350 mL/min. The column temperature was set to 30 ◦C. Thermo
XCaliber (v. 3.0.63) and Exactive (v. 1.1SP6) software were used for method development and data
acquisition in raw format (Figure S4).
For quantitative estimations, a standard curve was developed in the range of 2 ng/mL to 2000 ng/mL
of Kyn in 20% ACN with 0.1% FA in distilled water. The standard curve was replicated on three
different days to determine %CV and recovery (Table S4). Standards and samples were thawed and
kept at 20 ◦C. The collected medium was added into ACN with 0.1% FA at the ratio of 1:1. The samples
were vortexed for 40–50 s, centrifuged at 15,700× g for 15 min, and then 150 µL supernatant was taken
and analyzed.
4.10. Statistical Analysis
The data were expressed as the mean ± standard deviation. Differences between the groups
were analyzed using the Student’s t-test. A p-value < 0.05 was considered significant. Kaplan–Meier
analyses were performed for survival analysis. A log-rank test was used to compute the significance of
survival difference.
5. Conclusions
Our results suggest that liver metastasis from uveal melanoma express TDO and produce Kyn in
the tumor microenvironment. The expression of TDO in the liver metastasis may facilitate inhibition of
anti-tumor immunity and TDO may be an important target to improve the efficacy of immunotherapies
against MUM in the liver.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/2/405/s1.
Figure S1: Immunohistochemical (IHC) staining of 12 liver metastasis specimens, Figure S2: Whole blots for
western blot shown in Figure 3B, Figure S3: Characterization of UMp005 cell line, Figure S4: Representative XIC
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for Kyu (m/z: 209.09–209.1) and Trp (m/z: 205.09–205.1), Table S1: Summary of clinicopathological phenotypes of
80 patients with primary uveal melanoma in TCGA Database, Table S2: List of abbreviations in Figure 6A, Table S3:
Primer sequence of TDO2, IDO and GAPDH, Table S4: %CV and % recovery for Kyn linearity concentration
(2–2000 ng/mL) range for inter and intra-day runs.
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